NCT01622543 - Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

October 26, 2012

Primary Completion Date

January 18, 2017

Study Completion Date

September 12, 2018

Conditions

Colorectal Cancer

Interventions

DRUG

Folfox plus Bevacizumab and reolysin

FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter

DRUG

Folfox plus Bevacizumab

FOLFOX6/bevacizumab given every 14 days.

Trial Locations (10)

Tom Baker Cancer Centre, Calgary

BCCA - Vancouver Cancer Centre, Vancouver

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

Cancer Centre of Southeastern Ontario at Kingston, Kingston

London Regional Cancer Program, London

Ottawa Hospital Research Institute, Ottawa

Odette Cancer Centre, Toronto

Univ. Health Network-Princess Margaret Hospital, Toronto

McGill University - Dept. Oncology, Montreal

Allan Blair Cancer Centre, Regina